Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms

APMIS

Volumn 118, Issue 12, 2010, Pages 973-981

  Passero, Luiz Felipe Domingues ^a   Da Costa Bordon, Maria Luiza Antunes ^a   De Carvalho, Ana Kely ^a   Martins, Luciano Moura ^b   Corbett, Carlos Eduardo Pereira ^a   Laurenti, Márcia Dalastra ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Amastigote antigen; Immunization; Leishmania (Viannia) shawi; Promastigote antigen

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NITRIC ACID DERIVATIVE; PARASITE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; HUMORAL IMMUNITY; IMMUNIZATION; LEISHMANIA; LEISHMANIA SHAWI; LEISHMANIASIS; LYMPH NODE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; IMMUNIZATION; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; STATISTICS, NONPARAMETRIC;

EID: 78649506340     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02679.x     Document Type: Article

References (43)

1. Laurenti MD, Sotto MN, Corbett CE, Da Matta VL, Duarte MI. Experimental visceral leishmaniasis: sequential events of granuloma formation at subcutaneous inoculation site. Int J Exp Pathol 1990;71:791-7.
2. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 2008;19:394-406.
3. Haldar AK, Banerjee S, Naskar K, Kalita D, Islam NS, Roy S. Sub-optimal dose of sodium antimony gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio. Exp Parasitol 2009;122:145-54.
4. Sampaio RN, Lucas IC, Costa Filho AV. The use of azythromycin and N-methyl glucamine for the treatment of cutaneous Leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL6 mice. An Bras Dermatol 2009;84:125-38.
5. Muniz-Junqueira MI, De Paula-Coelho VN. Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-alpha production, but only via TNF-alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int Immunopharmacol 2008;8:1633-8.
6. Camizotti LA, Yamashiro-Kanashiro EH, Cotrim PC. Identification and chromosomal localization of one locus of Leishmania (L.) major related with resistance to itraconazole. Parasitol Res 2009;105:471-8.
7. Nagill R, Mahajan R, Sharma M, Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 2009;58:359-66.
8. Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 2007;25:7962-71.
9. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005;23:3642-8.
10. Bhaumik SK, Naskar K, De T. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Eur J Immunol 2009;39:2146-60.
11. Rosa R, Marques C, Rodrigues OR, Santos-Gomes GM. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response. Vaccine 2007;25:4525-32.
12. Stäger S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000;165:7064-71.
13. Soong L, Duboise SM, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995;63:3559-66.
14. Pral EM, Da Moitinho ML, Balanco JM, Teixeira VR, Milder RV, Alfieri SC. Growth phase and medium pH modulate the expression of proteinase activities and the development of megasomes in axenically cultivated Leishmania (Leishmania) amazonensis amastigote-like organisms. J Parasitol 2003;89:35-43.
15. Teixeira MC, De Jesus Santos R, Sampaio RB, Pontes-de-Carvalho L, Dos-Santos WL. A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species. Parasitol Res 2002;88:963-8.
16. Rochette A, Raymond F, Corbeil J, Ouellette M, Papadopoulou B. Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum. Mol Biochem Parasitol 2009;165:32-47.
17. Chan J, Fujiwara T, Brennan P, McNeil M, Turco SJ, Sibille JC, et al. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc Natl Acad Sci USA 1989;86:2453-67.
18. Bahr V, Stierhof YD, Ilg T, Demar M, Quinten M, Overath P. Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of L. mexicana. Mol Biochem Parasitol 1993;58:107-21.
19. Singal P, Singh PP. Leishmania donovani amastigote components-induced colony-stimulating factors production. Parasitol Int 2005;54:9-20.
20. Passero LFD, Sacomori JV, Tomokane TY, Corbett CE, Da Silveira FT, Laurenti MD. Ex vivo and in vivo biological behavior of Leishmania (Viannia) shawi. Parasitol Res 2009;105:1741-7.
21. Passero LFD, Marques C, Vale-Gato I, Corbett CEP, Laurenti MD, Santos-Gomes G. Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi. Parasitol Int 2010;59:159-65.
22. Todolí F, Solano-Gallego L, Ojeda A, Quintana J, Lloret A, Roura X, et al. Anti-Leishmania IgA in urine samples from dogs with clinical leishmaniasis. Vet Parasitol 2009;159:17-23.
23. Giunchetti RC, Reis AB, Da Silveira-Lemos D, Martins-Filho OA, Corrêa-Oliveira R, Bethony J, et al. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res Vet Sci 2008;85:106-12.
24. Boggiatto PM, Jie F, Ghosh M, Gibson-Corley KN, Ramer-Tait AE, Jones DE, et al. Altered dendritic cell phenotype in response to Leishmania amazonensis amastigote infection is mediated by MAP kinase, ERK. Am J Pathol 2009;174:1818-26.
25. Carrier Y, Yuan J, Kuchroo VK, Weiner HL. Th3 cells in peripheral tolerance. I. Induction of FoxP3-positive regulatory T cells by Th3 cells derived from TGF-β T cell-transgenic mice. J Immunol 2007;178:179-85.
26. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992;257:545-8.
27. Reed SG, Da Silva JS, Ho JL, Koehler JK, Russo DM, Pihl DL, et al. Cytokine activation of human macrophages infected with HIV-1 to inhibit intracellular protozoa. J Acquir Immune Defic Syndr 1992;5:666-75.
28. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005;6:600-7.
29. O'Daly JA, Lezama R, Rodriguez PJ, Silva E, Indriago NR, Peña G, et al. Antigens from Leishmania amastigotes induced clinical remission of psoriasis. Arch Dermatol Res 2009;301:1-13.
30. O'Daly JA, Lezama R, Gleason J. Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis. Arch Dermatol Res 2009;301:411-27.
31. O'Daly JA, Rodriguez B, Ovalles T, Pelaez C. Lymphocyte subsets in peripheral blood of patients with psoriasis before and after treatment with leishmania antigens. Arch Dermatol Res 2010;302:95-104.
32. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8.
33. Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009;129:1100-14.
34. Souza-Neto SM, Carneiro CM, Vieira LQ, Afonso LCC. Leishmania braziliensis: partial control of experimental infection by interleukin-12 p40 deficient mice. Mem Inst Oswaldo Cruz 2004;99:289-94.
35. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
36. Ota H, Takashima Y, Matsumoto Y, Hayashi Y, Matsumoto Y. Pretreatment of macrophages with the combination of IFN-gamma and IL-12 induces resistance to Leishmania major at the early phase of infection. J Med Vet Sci 2008;70:589-93.
37. Lezama-Dávila CM, Isaac-Márquez AP, Barbi J, Cummings HE, Lu B, Satoskar AR. Role of phosphatidylinositol-3-kinase-gamma (PI3Kgamma)-mediated pathway in 17beta-estradiol-induced killing of L. mexicana in macrophages from C57BL/6 mice. Immunol Cell Biol 2008;86:539-43.
38. Pakpour N, Zaph C, Scott P. The central memory CD4+ T cell population generated during Leishmania major infection requires IL-12 to produce IFN-gamma. J Immunol 2008;180:8299-305.
39. + cells correlates with resolution of lesions in murine cutaneous leishmaniasis. J Immunol 1992;149:2715-21.
40. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+ CD25- T cells to CD4+ CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86.
41. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420:502-7.
42. Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as example. Cell Microbiol 2008;10:1221-34.
43. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-B1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.